Madrigal Pharmaceuticals, Inc. (MDGL) Dividend History

Company News

• Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

  Madrigal Pharmaceuticals announced positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra, demonstrating significant improvements in liver stiffness, liver fat, fibrosis biomarkers, liver volume, and risk scores for clinically significant portal hypertension.

  GlobeNewswire Inc.
• Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

  Madrigal Pharmaceuticals reported positive two-year data for its drug Rezdiffra in treating compensated MASH cirrhosis, showing significant reductions in liver stiffness. The company also reported better-than-expected Q4 financial results.

  Benzinga
• Why Madrigal Pharmaceuticals Stock Is Soaring Today

  Madrigal Pharmaceuticals reported strong Q4 2024 results, with revenue and earnings beating analyst estimates. The company also announced positive new two-year data from a phase 3 study of its MASH drug Rezdiffra, adding to the optimism about the drug's potential.

  The Motley Fool
• Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings? - Zacks Investment Research

  Viking Therapeutics, a biotech firm without any marketed drugs, is set to report its Q2 earnings. Investors will focus on updates related to its pipeline candidates, including VK2809 for NASH and VK2735 for obesity. The company's strong cash balance and robust pipeline development provide growth potential, though it faces competition in the obesity market.

  Zacks Investment Research

  Featured Companies: LLY VKTX
• Madrigal’s stock surges as FDA approves first drug for liver disease MASH

  Madrigal Pharmaceuticals on Thursday received the FDA’s first approval of a drug designed to treat a severe liver disease known as MASH.

  MarketWatch

  Featured Companies: AKRO ETNB LLY